- Home
- LEE vs CUE Comparison
LEE vs CUE Comparison
Compare LEE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEE | CUE |
|---|---|---|
| Founded | 1890 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 177.0M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LEE | CUE |
|---|---|---|
| Price | $6.86 | $18.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $88.00 |
| AVG Volume (30 Days) | 33.4K | ★ 135.7K |
| Earning Date | 11-25-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $543,955,000.00 | $27,466,000.00 |
| Revenue This Year | $4.44 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $3.34 | $0.17 |
| 52 Week High | $11.88 | $45.50 |
Technical Indicators
Market Signals| Indicator | LEE | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 43.03 |
| Support Level | $6.69 | $18.20 |
| Resistance Level | $7.66 | $22.49 |
| Average True Range (ATR) | 0.43 | 1.93 |
| MACD | 0.12 | 0.27 |
| Stochastic Oscillator | 85.15 | 29.53 |
Price Performance
Historical ComparisonAbout LEE Lee Enterprises Incorporated
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.